Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications

BACKGROUND: Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Husmann, Rachel, Davies, John B., Ghannam, Malik, Berry, Brent, Kelkar, Praful
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066779/
https://www.ncbi.nlm.nih.gov/pubmed/32190009
http://dx.doi.org/10.1186/s12948-020-00119-4
_version_ 1783505309146284032
author Husmann, Rachel
Davies, John B.
Ghannam, Malik
Berry, Brent
Kelkar, Praful
author_facet Husmann, Rachel
Davies, John B.
Ghannam, Malik
Berry, Brent
Kelkar, Praful
author_sort Husmann, Rachel
collection PubMed
description BACKGROUND: Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops. CASE PRESENTATION: A 38-year-old Caucasian female patient with history of relapsing–remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod. CONCLUSION: FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up.
format Online
Article
Text
id pubmed-7066779
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70667792020-03-18 Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications Husmann, Rachel Davies, John B. Ghannam, Malik Berry, Brent Kelkar, Praful Clin Mol Allergy Case Report BACKGROUND: Fingolimod, an immunomodulatory agent, is used for the treatment of relapsing–remitting multiple sclerosis (RRMS). Fingolimod-associated macular edema (FAME) is a known complication with an incidence of 0.4%. The current recommendation for treatment of FAME is cessation of fingolimod. There are few case reports with management of FAME with steroid eye drops. CASE PRESENTATION: A 38-year-old Caucasian female patient with history of relapsing–remitting multiple sclerosis (RRMS) and treated with fingolimod developed Fingolimod-associated macular edema (FAME). Nevertheless, FAME was successfully treated with nonsteroidal anti-inflammatory eye drops without discontinuation of fingolimod. CONCLUSION: FAME may be managed with non-steroidal eye drops without discontinuation of fingolimod in appropriate patient monitored with close follow up. BioMed Central 2020-03-12 /pmc/articles/PMC7066779/ /pubmed/32190009 http://dx.doi.org/10.1186/s12948-020-00119-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Husmann, Rachel
Davies, John B.
Ghannam, Malik
Berry, Brent
Kelkar, Praful
Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
title Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
title_full Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
title_fullStr Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
title_full_unstemmed Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
title_short Fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
title_sort fingolimod-associated macular edema controlled with nepafenac non-steroidal anti-inflammatory opthalmologic applications
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066779/
https://www.ncbi.nlm.nih.gov/pubmed/32190009
http://dx.doi.org/10.1186/s12948-020-00119-4
work_keys_str_mv AT husmannrachel fingolimodassociatedmacularedemacontrolledwithnepafenacnonsteroidalantiinflammatoryopthalmologicapplications
AT daviesjohnb fingolimodassociatedmacularedemacontrolledwithnepafenacnonsteroidalantiinflammatoryopthalmologicapplications
AT ghannammalik fingolimodassociatedmacularedemacontrolledwithnepafenacnonsteroidalantiinflammatoryopthalmologicapplications
AT berrybrent fingolimodassociatedmacularedemacontrolledwithnepafenacnonsteroidalantiinflammatoryopthalmologicapplications
AT kelkarpraful fingolimodassociatedmacularedemacontrolledwithnepafenacnonsteroidalantiinflammatoryopthalmologicapplications

Ejemplares similares